

BILL SUMMARY
1st Session of the 57th Legislature

Bill No.:	SB 848
Version:	CS
Request Number:	8760
Author:	Rep. Echols
Date:	4/23/2019
Impact:	OMES & Insurance: \$0 OBN: \$0

Research Analysis

The CS to SB 848 modifies continuing education requirements for licensees of the State Board of Medical Examiners. Continuing education courses shall include at least two hours in pain management or two hours in opioid use and addiction. Dentists are required by the measure to take three hours in pain management or three hours in opioid use and addiction. Physician assistants, optometrists, osteopaths, and veterinarians are required to take one hour on pain management or one hour on opioid use and addiction. Licensees are exempt from the continuing education requirement created by this measure if they can provide evidence to the licensing board that the licensee does not currently hold a valid federal Drug Enforcement Administration registration number.

The measure directs pharmacists to fill a prescription for a Schedule II opioid prescription to the specified dose in the prescription order. Any expert testifying against a licensee must be a Board-certified physician practicing the specialty of the licensee named in the complaint. The measure strikes language allowing the Board to review a physician's prescription practices with regards to prescribing opioids in excess of the maximum dosage. The measure provides that failure of a registrant to access and check the central repository may be grounds for the licensing board of the registrant to take disciplinary action.

Unless a prescribed opioid or pain treatment is classified as a Schedule II drug, the measure strikes the requirement for the prescription to be capped at a seven day supply and does not require a pain management prescription to be prescribed at the lowest effective dose. The measure outlines acceptable circumstances wherein a Schedule II opioid drug may be prescribed for pain.

The measure directs the Insurance Department to study the effects of restricting opioid prescriptions on the claims paid by health insurance carriers and the out-of-pocket costs. The Department shall complete and submit the report to the standing health committees in the Senate and House no later than January 1, 2021.

The measure directs the Oklahoma State Bureau of Narcotics and Dangerous Drugs to report to the relevant standing House and Senate committees over health and human services matters and over occupational and professional regulation matters regarding the use of the central repository, continuing education requirements, number of patients taking more than 100 morphine milligram equivalents and data regarding the total quantity of prescribed morphine milligram equivalents.

The measure repeals Section 6, Chapter 175, O.S.L. 2018 relating to a noncodified section of HB 1446 which directed the Insurance Department to evaluate the limits on prescriptions for opioid medication.

Prepared By: Brad Wolgamott

Fiscal Analysis

The CS on SB 848 is not anticipated to create any fiscal or revenue considerations for the state.

Prepared By: Kristina King

Other Considerations

None.

© 2019 Oklahoma House of Representatives, see Copyright Notice at www.okhouse.gov